Correlation Engine 2.0
Clear Search sequence regions

  • academy (1)
  • AURKA (2)
  • breast cancer (9)
  • cohort (8)
  • ESR1 (6)
  • FGD3 (11)
  • meta analysis (2)
  • MKI67 (2)
  • prognostic (5)
  • rnas (4)
  • society (1)
  • SUSD3 (1)
  • tamoxifen (1)
  • taxonomy (1)
  • women (2)
  • Sizes of these terms reflect their relevance to your search.

    Identification of single-gene biomarkers that are prognostic of outcome can shed new insights on the molecular mechanisms that drive breast cancer and other cancers. Exploratory analysis of 20,464 single-gene messenger RNAs (mRNAs) in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) discovery cohort indicates that low expression of FGD3 mRNA is prognostic for poor outcome. Prognostic significance of faciogenital dysplasia 3 (FGD3), SUSD3, and other single-gene proliferation markers was evaluated in breast cancer and The Cancer Genome Atlas (TCGA) cohorts. A meta-analysis of Cox regression of FGD3 mRNA as a continuous variable for overall survival of estrogen receptor (ER)-positive samples in METABRIC discovery, METABRIC validation, TCGA breast cancer, and Combination Chemotherapy in Treating Women With Breast Cancer (E2197) cohorts resulted in a combined hazard ratio (HR) of 0.69 (95% CI, 0.63 to 0.75), indicating better outcome with high expression. In the ER-negative samples, the combined meta-analysis HR was 0.72 (95% CI, 0.63 to 0.82), suggesting that FGD3 is prognostic regardless of ER status. The potential of FGD3 as a biomarker for freedom from recurrence was evaluated in the Breast International Group 1-98 (BIG 1-98; Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer) study (HR, 0.85; 95% CI, 0.76 to 0.93) for breast cancer-free interval. In the Hungarian Academy of Science (HAS) breast cancer cohort, splitting on the median had an HR of 0.49 (95% CI, 0.42 to 0.58) for recurrence-free survival. A comparison of the Stouffer P value in five ER-positive cohorts showed that FGD3 (P = 3.8E-14) outperformed MKI67 (P = 1.06E-8) and AURKA (P = 2.61E-5). A comparison of the Stouffer P value in four ER-negative cohorts showed that FGD3 (P = 3.88E-5) outperformed MKI67 (P = .477) and AURKA (P = .820). FGD3 was previously shown to inhibit cell migration. FGD3 mRNA is regulated by ESR1 and is associated with favorable outcome in six distinct breast cancer cohorts and four TCGA cancer cohorts. This suggests that FGD3 is an important clinical biomarker. © 2017 by American Society of Clinical Oncology.


    Scooter Willis, Yuliang Sun, Mark Abramovitz, Teng Fei, Brandon Young, Xiaoqian Lin, Min Ni, Justin Achua, Meredith M Regan, Kathryn P Gray, Robert Gray, Victoria Wang, Bradley Long, Roswitha Kammler, Joseph A Sparano, Casey Williams, Lori J Goldstein, Roberto Salgado, Sherene Loi, Giancarlo Pruneri, Giuseppe Viale, Myles Brown, Brian Leyland-Jones. High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. JCO precision oncology. 2017;1

    PMID: 32913979

    View Full Text